FindTrial
Sign In

TAVR Implantation with SAPIEN XT

DEVICE2 trials

Sponsors

Edwards Lifesciences

Conditions

Calcific Aortic StenosisSevereSymptomaticSymptomatic Severe Aortic Stenosis

Unknown Phase

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk
CompletedNCT01314313
Edwards LifesciencesSymptomatic Severe Aortic Stenosis
Start: 2011-03-31End: 2024-01-17Updated: 2024-03-07
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B
CompletedNCT02184442
Edwards LifesciencesCalcific Aortic Stenosis, Severe, Symptomatic
Start: 2011-03-09End: 2017-05-30Updated: 2018-09-25

Related Papers

Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients.
2023-07-0130 citations
Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials.
2023-02-0140 citations
Neutrophil‐to‐Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries
Journal of the American Heart Association2022-06-0327 citations
Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement.
2022-05-17113 citations
Time-of-Day and Clinical Outcomes After Surgical or Transcatheter Aortic Valve Replacement: Insights From the PARTNER Trials
Circulation Cardiovascular Quality and Outcomes2022-01-017 citations
Impact of Flow on Prosthesis-Patient Mismatch Following Transcatheter and Surgical Aortic Valve Replacement
Circulation Cardiovascular Imaging2021-08-0130 citations
Incidence and Clinical Significance of Worsening Tricuspid Regurgitation Following Surgical or Transcatheter Aortic Valve Replacement: Analysis From the PARTNER IIA Trial
Circulation Cardiovascular Interventions2021-07-1626 citations
Atrial Fibrillation Is Associated With Mortality in Intermediate Surgical Risk Patients With Severe Aortic Stenosis: Analyses From the PARTNER 2A and PARTNER S3i Trials
Journal of the American Heart Association2021-03-2315 citations
Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial.
2020-10-01139 citations
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement
New England Journal of Medicine2020-01-29761 citations
Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry
European Heart Journal2019-12-0240 citations
Prosthetic Valve Endocarditis After TAVR and SAVR
Circulation2019-11-06109 citations
Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement.
2019-09-0136 citations
Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement
Circulation Heart Failure2019-08-0147 citations
New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial
European Heart Journal2019-04-01142 citations
Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk
Circulation2019-01-17167 citations
Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve
JAMA Cardiology2017-10-03206 citations
Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk
JAMA Cardiology2017-06-28131 citations
Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry.
2017-05-01231 citations
Computed Tomography-Based Oversizing Degrees and Incidence of Paravalvular Regurgitation of a New Generation Transcatheter Heart Valve.
2017-04-0140 citations

6 more papers not shown